XML 50 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Acquisition of EGEN Assets (Details Textual) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Jun. 16, 2017
Jun. 20, 2014
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Jun. 30, 2017
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)     $ 2,520,000 $ 2,520,000    
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability         (1,246,151)      
Finite-Lived Intangible Assets, Net     852,437   852,437   $ 1,022,924  
Noncompete Agreements [Member]                
Amortization of Intangible Assets     56,829   170,487      
Finite-Lived Intangible Assets, Net     852,437   852,437   1,022,924  
Finite-Lived Intangible Assets, Accumulated Amortization     738,777   738,777   $ 568,290  
EGEN Inc [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   $ 30,400,000 30,400,000   30,400,000      
Payments to Acquire Businesses, Gross   $ 3,000,000            
Stock Issued During Period, Shares, Acquisitions   193,728            
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 47,862              
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability     1,246,151 $ 662,410 670,172 $ 556,382    
Goodwill, Acquired During Period   $ 2,000,000            
EGEN Inc [Member] | Noncompete Agreements [Member]                
Finite-Lived Intangible Asset, Useful Life             7 years  
EGEN Inc [Member] | Indefinite-lived in Process Research and Development [Member]                
Indefinite-lived Intangible Assets Acquired   24,200,000 6,900,000   9,400,000      
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)             $ 1,400,000  
Asset Impairment Charges     2,500,000          
Business Combination, Contingent Consideration, Liability     12,500,000   12,500,000     $ 13,800,000
EGEN Inc [Member] | Ovarian Cancer Study Milestone [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     12,400,000   12,400,000      
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer Study Milestone [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     12,000,000   12,000,000      
EGEN Inc [Member] | TheraSilence Technology Milestone [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     $ 6,000,000   $ 6,000,000      
EGEN Inc [Member] | Maximum [Member]                
Business Combination, Consideration Transferred   $ 44,400,000